Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v20-EN Version v9-FR
Language English French
Date Updated 2022-03-26 2020-09-22
Drug Identification Number 02354624 02354624
Brand name TEVA-ROSUVASTATIN TEVA-ROSUVASTATIN
Common or Proper name ROSUVASTATIN 20MG TAB ROSUVASTATIN 20MG TAB
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients ROSUVASTATIN ROSUVASTATIN
Strength(s) 20MG 20MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 30's 30's
ATC code C10AA C10AA
ATC description LIPID MODIFYING AGENTS, PLAIN LIPID MODIFYING AGENTS, PLAIN
Reason for shortage Other (Please describe in comments) Shortage of an inactive ingredient or component.
Anticipated start date
Actual start date 2020-07-14 2020-07-14
Estimated end date 2021-01-31
Actual end date 2022-03-25
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Item is transitioned/discontinued Allocating 100% of Teva market share until October 2020.
Health Canada comments